CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Stanford University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Breast Cancer

Treatments: Procedure: high dose chemo then auto hematopoietic cell transplant

Study type: Interventional

Funder types: Other

Identifiers

NCT00186680

NCT00186680

BMT86

Details and patient eligibility

About

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Full description

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Enrollment: 99 estimated patients

Sex: All

Ages: 19 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- stage IV breast cancer

• primary breast cancer does not express CD34+
• adequate organ function
• no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks
• CNS disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)